Raleigh, North Carolina19 days ago
ul>HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI.
Support clinical development and research initiatives across development at the request of R&D to include, but not limited to, site evaluation and identification, recruitment, investigator meetings, external expert identification, and involving experts to generate scientific data including investigator-sponsored trials.